NCT05082415View on ClinicalTrials.gov

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

CompletedOBSERVATIONAL
Enrollment

9,456

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
Age-related Macular Degeneration (AMD)
Interventions
DRUG

Brolucizumab

Participants received brolucizumab injection during the index period

Trial Locations (1)

07936-1080

Novartis Pharmaceuticals, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY